Business Wire

iProov Reports Record Year As Demand For Secure Online Identity Verification Soars

Share

iProov, the world leader in biometric face authentication, today announced yet another record year of growth as global demand for online identity verification continues to soar.

iProov’s revenue for 2021 has tripled last year’s results, marking a major milestone for the company. During a single 10-day period in 2021, online verifications surpassed the number achieved in the whole of 2020. In addition, iProov delivered more than 1 million verifications in a single day several times throughout the year. To meet the increased demand for iProov’s award-winning services, the company increased staff by 64% across all business areas and geographies from December 2020 through December 2021, with a focus on adding even more new iProovers in 2022.

“iProov is giving people access to what is quickly becoming a basic human right: the ability to assert your identity online safely, securely and ubiquitously, with your privacy protected,” said Andrew Bud, Founder and CEO, iProov. “That higher mission is what drives everyone at iProov to work in such a focused and productive way. The result is a profitable year, ending with a very strong and robust cash position alongside many successful achievements across our business.”

2021 saw iProov continue to meet the rapidly scaling needs of large customers and partners around the globe. These included the Australian Taxation Office, which chose iProov’s Genuine Presence Assurance™ in March to enable Australians to set up their myGovID digital identity, providing access to services including managing tax returns, accessing health services and applying for benefits. Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, added iProov’s Liveness Assurance and Genuine Presence Assurance to its platform to combat online crime and fraud worldwide. itsme, Belgium’s digital identity app, selected Genuine Presence Assurance to support its global expansion. And within the rapidly-evolving crypto space, Synaps, the Paris-based provider of digital identity services for cryptocurrency, also implemented Genuine Presence Assurance.

iProov closed out the year by working with Eurostar on the launch of a trial of its contactless fast-track travel service. SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. Once at the station, passengers can choose to proceed through a dedicated SmartCheck lane with two face scans, eliminating the need to produce electronic or paper documentation.

2021 also saw an increase in demand for Genuine Presence Assurance in a variety of new applications and settings. iProov announced it is working with the National Science Foundation, University of Washington and MATTR to produce a flexible proof-of-concept technology to tackle the issue of verifying the source of online information and its reliability.

iProov also won a number of awards in 2021. These included recognition in the Deloitte Fast 50 of fastest-growing technology companies in the UK for the second year in a row and the naming of Andrew Bud as one of the Top 50 Most Ambitious Business Leaders. Earlier in 2021, iProov took home the highly regarded 2021 Global InfoSec Award for Biometrics Next-Gen, three Cybersecurity Excellence Awards and a Cyber Security Global Excellence Award for Best Biometric Solution.

“One of our values at iProov is that we ‘Achieve the Remarkable’ and we have certainly done that in 2021, in so many ways,” said Bud. “While we celebrate our achievements, we now look forward to the infinite opportunities and growth prospects that lie ahead for iProov in 2022.”

-Ends-

About iProov

Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rob Tacey
rob.tacey@iproov.com
iProov

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 15:39:00 EEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye